Tissue Regenix Group, the regenerative medical devices company has secured a Group Purchasing Organisation (GPO) contract with Premier Inc., a leading healthcare improvement company.
DermaPure has been awarded the contract under a ‘Breakthrough Technology Agreement’, which is awarded by the GPO.
The Premier alliance is comprised of approximately 3,600 U.S. based hospitals and 120,000 other healthcare providers which will now have contracted access to DermaPure.
Antony Odell, CEO, Tissue Regenix Group plc commented: “Approval under Premier’s Breakthrough Technology Agreement marks a significant milestone for DermaPure. This confirms the unique characteristics of our patented dCELL Technology, the powerful clinical evidence we have collected, and the remarkable outcomes it achieves in real world clinical situations.”